Merck's sugammadex gets 2nd chance at US FDA
This article was originally published in Scrip
Executive Summary
The US FDA is giving Merck's application for sugammadex sodium injection a second chance, accepting the firm's resubmission, with an expected completion date for the agency's review in the first half of the year, the New Jersey drug maker said.